Previous Close | 215.74 |
Open | 209.27 |
Bid | 200.01 x 1100 |
Ask | 201.90 x 800 |
Day's Range | 198.19 - 216.15 |
52 Week Range | 173.45 - 371.16 |
Volume | |
Avg. Volume | 1,212,222 |
Market Cap | 31.224B |
Beta (5Y Monthly) | 1.12 |
PE Ratio (TTM) | 46.38 |
EPS (TTM) | 4.28 |
Earnings Date | Feb 08, 2023 - Feb 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 253.47 |
Subscribe to Yahoo Finance Plus to view Fair Value for ILMN
Illumina beat sales estimates, but profit came in light during the fourth quarter. That led ILMN stock to fall Wednesday.
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to the Broad Institute. Alex Aravanis, PhD, chief technology officer of Illumina, made the announcement today in a presentation at the Advances in Genome Biology and Technology (AGBT) conference in Hollywood, Florida. Aravanis also announced much anticipated updates on Illumina's innovation roadmap including Illumina Complete Lo
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.